Ridder Titan Genesis Corp.
RTGC
Other OTC0.13
USD
-0.34
- -
Ridder Titan Genesis Corp.
RTGC
(Other OTC)
Recent
price
0.13
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ridder Titan Genesis Corp. (RTGC) is a medical cannabis-focused company that develops proprietary whole-plant extracts and cannabinoid-based pharmaceutical concepts for therapeutic use. The firm aims to create differentiated pharmaceutical products derived from cannabis across clinical indications, pursuing both therapeutic applications and regulatory pathways for market approval. The company operates in the United States with core activities centered on research, development, and commercialization of cannabis-derived formulations, including standardized extracts and associated delivery systems. Founding year and headquarters Ridder Titan Genesis Corp. traces its origins to 1988 and is headquartered in Boulder, Colorado, United States, with a strategic focus on building a scalable platform for cannabinoid-based medicines. The company maintains a corporate structure designed to support translational research, formulation development, and potential partnerships within the broader biopharmaceutical landscape. Main products and services - Proprietary whole-plant cannabis extracts: development, characterization, and optimization of standardized extracts for therapeutic use; inclusion of multi-cannabinoid profiles and supportive pharmacological data. - Cannabinoid-derived pharmaceuticals: research and development of drug candidates intended for clinical trials, regulatory submission, and potential commercialization. - Formulation and delivery systems: development of dosage forms and delivery modalities to optimize bioavailability and patient adherence. - Translational research services: preclinical studies, pharmacokinetics, and safety assessments to support clinical program milestones. - Technical services and consulting: regulatory strategy support, quality control frameworks, and analytical method development for cannabis-derived products. Latest major company changes - Strategic rebranding and corporate positioning: the company has pursued name changes and repositioning to emphasize its focus on cannabinoid-based therapeutics and pharmaceutical development. - Strategic partnerships and alliances: engages in collaborations with contract research organizations and potential industry partners to advance clinical programs and regulatory milestones. - Organizational and governance updates: has implemented organizational adjustments to support expanded R&D and regulatory activities, including possible realignments of leadership responsibilities to accelerate product development. Industry context and markets - Industry and segments: operates within the medical cannabis and pharmaceutical development sector, focusing on drug development and translational research for cannabinoid therapies. - Target markets: aims at healthcare providers, research institutions, and potential licensing partners for cannabinoid-based medicines. - Geographic operations: primarily based in the United States with development activities and regulatory considerations aligned to U.S. markets; potential for international collaboration and later expansion. - Corporate relationships: operates as an independent entity with potential affiliations to parent or affiliated entities within the broader UMF/RTGC corporate lineage, focused on pharmaceutical development rather than consumer cannabis products.